MX2024005855A - Procedimientos para tratar el cancer. - Google Patents

Procedimientos para tratar el cancer.

Info

Publication number
MX2024005855A
MX2024005855A MX2024005855A MX2024005855A MX2024005855A MX 2024005855 A MX2024005855 A MX 2024005855A MX 2024005855 A MX2024005855 A MX 2024005855A MX 2024005855 A MX2024005855 A MX 2024005855A MX 2024005855 A MX2024005855 A MX 2024005855A
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
pharmaceutically acceptable
pharmaceutical compositions
acceptable salts
Prior art date
Application number
MX2024005855A
Other languages
English (en)
Spanish (es)
Inventor
David Witty
Kevin Mcdonnell
Punit Upadhyaya
Shawn Watson
Dominic Smethurst
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2024005855A publication Critical patent/MX2024005855A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024005855A 2021-11-16 2022-11-16 Procedimientos para tratar el cancer. MX2024005855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163264132P 2021-11-16 2021-11-16
PCT/GB2022/052903 WO2023089308A1 (en) 2021-11-16 2022-11-16 Methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2024005855A true MX2024005855A (es) 2024-05-28

Family

ID=84535807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005855A MX2024005855A (es) 2021-11-16 2022-11-16 Procedimientos para tratar el cancer.

Country Status (9)

Country Link
EP (1) EP4433025A1 (https=)
JP (1) JP2024543505A (https=)
KR (1) KR20240100420A (https=)
CN (1) CN118475345A (https=)
AU (1) AU2022390670A1 (https=)
CA (1) CA3237681A1 (https=)
IL (1) IL312680A (https=)
MX (1) MX2024005855A (https=)
WO (1) WO2023089308A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
WO2025125648A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide complex for use in treating cancer
WO2025125652A1 (en) * 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物

Also Published As

Publication number Publication date
KR20240100420A (ko) 2024-07-01
WO2023089308A1 (en) 2023-05-25
CA3237681A1 (en) 2023-05-25
EP4433025A1 (en) 2024-09-25
AU2022390670A1 (en) 2024-05-23
CN118475345A (zh) 2024-08-09
JP2024543505A (ja) 2024-11-21
IL312680A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
MX2024005855A (es) Procedimientos para tratar el cancer.
MX2022006001A (es) Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos.
MX2023008954A (es) Inhibidores de los receptores erbb.
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2021007773A (es) Compuestos inhibidores de egfr.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
WO2020154519A3 (en) Methods of treating addiction
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
EP4596048A3 (en) Cd73 inhibitors
MX2025007174A (es) Dispersion solida de un inhibidor de her2
WO2018187331A8 (en) Macrocyclic compound and uses thereof
MX2023013715A (es) Regímenes de dosis de ecubectedina.
PH12019500043A1 (en) Novel benzenesulfonamide compositions for treatment of malignant pleural effusions
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MY209459A (en) Peptide conjugates of microtubule-targeting agents as therapeutics
ZA202210640B (en) Deuterated oxophenylarsine compound and use thereof
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
PH12021553177A1 (en) Pharmaceutical composition for treating tumor
EP4467138A3 (en) Therapeutic agents for neurodegenerative diseases
MX2025007170A (es) Esquema de dosificacion de una dispersion solida de un inhibidor de her2
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
SA521421375B1 (ar) عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها
ZA201908087B (en) Treatment for migraine
PH12021550323A1 (en) Dendrimer formulations